Clareo Health | Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer
Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer
Assessd as resectable PDAC before surgical procedure
Voluntary to donate tumor samples resected in curative surgery for PDAC
Voluntary to participate in the radiological evaluation, tests of serum tumor markers, and the collection of MRD samples according to the study protocol
ECOG state (PS) grades ≤ 2
Voluntary to sign informed consent and adhering to the requirements and limitations outlined by lCD and this protocol
Confimed as pancreatic ductal adenocarcinoma by pathology
RO or R1 resection
Clinically evalutated eligible for adjuvant therapy
Tumor tissue samples meet the requirements of whole exome sequencing (WES)
You may not be if
Preoperative imaging examinations show distant metastasis
Have received neoadjuvant therapy
Have any other active malignancy within 5 years before enrollment, or have any other indolent cancers that did not interfere with the primary cancer assessment in the study without prior approval from the research committee
With other physical or mental conditions that may increase the risk of study participation or (in the investigator's judgment) may make the subject ineligible for study participation, including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormalities
Have participated in other interventional or observational clinical studies
